Drug Trial Radar · NCT05767892
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
May 1, 2023
Primary completion
Jul 30, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Mar 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups YK-029A group or Platinum-based chemotherapy group. Participants will receive YK-029A orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
YK-209A tabletDrug
YK-029A 200 milligram (mg) , orally without food,once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
Pemetrexed+carboplatin/CisplatinDrug
Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 .Time frame: Up to approximately 36 months after the first participant is randomized.
Locations
52 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Peking University Cancer Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical Colleg
Bengbu, Anhui, China
Anhui Provincial Chest Hospital
Hefei, Anhui, China
Anhui Provincial Hospital
Hefei, Anhui, China
Yijishan Hospital of Wannan Medical College
Wuhu, Anhui, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Cancer Hospital Affiliated to Guangzhou Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China
People's Hospital of Zhongshan City
Zhongshan, Guangdong, China
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
he First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhenzhou, Henan, China
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Third Xiangya Hospital, Central South University
Changsha, Hunan, China
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow Universit
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
Jilin Provincial Cancer Hospital
Changchun, Jilin, China
he First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Cancer Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Affiliated Hospital of Jining Medical University
Jining, Shandong, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.